Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vireo Growth's Enterprise Value for the quarter that ended in Jun. 2026 was $841.7 Mil.
Vireo Growth's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth EV-to-EBIT Related Terms
Vireo Growth EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vireo Growth's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vireo Growth's EV-to-EBIT falls into.
Vireo Growth's current Enterprise Value is $933.4 Mil.
Vireo Growth's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (VREOF) has a EV-to-EBIT of 51.83 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #575 out of 684 companies in the Drug Manufacturers industry, placing it in the top 84.1%.
Is Vireo Growth's EV-to-EBIT too high?
Vireo Growth's current EV-to-EBIT is 51.83. The Drug Manufacturers industry median EV-to-EBIT is 16.02. Vireo Growth's value of 51.83 is 223.5% above this industry median. Based on the distribution chart, Vireo Growth ranks #575 out of 684 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #575 out of 684 companies for EV-to-EBIT. This places Vireo Growth in the lower half of its industry. The industry median EV-to-EBIT is 16.02. Vireo Growth's value of 51.83 is 223.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.02, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current EV-to-EBIT of 51.83 is 223.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current EV-to-EBIT is 51.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $11.60, compared to a current price of $10.80 — trading 6.9% below its estimated fair value. The current EV-to-EBIT is 51.83 and 223.5% above the Drug Manufacturers industry median of 16.02. Vireo Growth's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vireo Growth (VREOF), the current EV-to-EBIT is 51.83 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (VREOF) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be undervalued.
The current stock price of $10.80 is trading 6.9% below its estimated GF Value™ of $11.60.
GuruFocus considers Vireo Growth to be Fairly Valued.
Key valuation signals for VREOF:
EV-to-EBIT: 51.83
GF Value™: $11.60 vs. price of $10.80 (6.9% below fair value)
Industry Position: 223.5% above the Drug Manufacturers median (#575 of 684)
No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
47GF Score
Get the complete analysis for VREOF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VREOF has been successfully added to your 
